The inflammatory milieu in the kidney is one of the major contributors to renal fibrosis (Lv et al., 2018), which in turn facilitates REP conversion into myofibroblasts and the concomitant loss of EPO production capability (Asada et al., 2011; Souma et al., 2013). Here, EPO is linked to renal fibrosis.